Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma, Kaposi 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Multi-centric Castleman's Disease 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Hodgkin Disease 1HTLV-I Infections 1Epstein-Barr Virus Infections 1Castleman Disease 1Acquired Immunodeficiency Syndrome 1

Interventions

Valganciclovir 2Rituximab 2tocilizumab 1human papillomavirus vaccine, L1 type 16, 18 1Zidovudine 1Watchful Waiting 1Vincristine 1Tobacco Use Cessation Devices 1Surveys and Questionnaires 1Sugars 1Rapid Diagnostic Tests 1Prednisone 1Observation 1Methotrexate 1Maltose 1Light Coagulation 1Leucovorin 1Laser Therapy 1Interviews as Topic 1Interferon-alpha 1Imiquimod 1Fluorouracil 1Filgrastim 1Etoposide 1Enzyme-Linked Immunosorbent Assay 1Electrocoagulation 1Doxorubicin 1Cyclophosphamide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Acquired Immunodeficiency Syndrome × Zidovudine × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡